Iambic Therapeutics targets up to $806 million IPO valuation
The Nvidia-backed biotech aims to raise as much as $159.4 million in its US initial public offering, according to a regulatory filing.
Story updates
12:36:13 PM UTC
SquawkNews
By Colin KellaherIambic Therapeutics on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering price.At the $16 midpoint of that price range, the San Diego technology and clinical-stage life-sciences company said it expects net proceeds…